Cite
HARVARD Citation
Chekerov, R. et al. (2018). Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet oncology. 19 (9), pp. 1247-1258. [Online].